Formosa Pharmaceuticals Files Clinical Trial Application for TSY-110, an Antibody-Drug Conjugate Biosimilar Targeting HER2-Positive Breast Cancers

Trial StartTSY-110KadcylaPositive

AI Analysis

Summary

Formosa Pharmaceuticals filed a Clinical Trial Application for TSY-110, an antibody-drug conjugate biosimilar targeting HER2-positive breast cancer, positioning it as a potential first-to-market biosimilar alternative to Roche's Kadcyla in major regulated markets.

Outcome Details

Clinical Trial Application filed for TSY-110, an antibody-drug conjugate biosimilar

Importance:6/10

Sentiment:

0.60

biosimilarADCHER2breast cancerclinical trialKadcyla competitor

Related Companies

$RHHBY

Read the original article

Published by PR Newswire Biotech on August 28, 2026 12:03 PM

Read Original